- Home
- TENX vs CARM Comparison
TENX vs CARM Comparison
Compare TENX & CARM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TENX
- CARM
- Stock Information
- Founded
- TENX 1967
- CARM 2016
- Country
- TENX United States
- CARM United States
- Employees
- TENX N/A
- CARM N/A
- Industry
- TENX Biotechnology: Pharmaceutical Preparations
- CARM Biotechnology: Pharmaceutical Preparations
- Sector
- TENX Health Care
- CARM Health Care
- Exchange
- TENX Nasdaq
- CARM Nasdaq
- Market Cap
- TENX 21.7M
- CARM 17.5M
- IPO Year
- TENX N/A
- CARM N/A
- Fundamental
- Price
- TENX $6.30
- CARM $0.22
- Analyst Decision
- TENX Strong Buy
- CARM Hold
- Analyst Count
- TENX 3
- CARM 5
- Target Price
- TENX $16.00
- CARM $0.90
- AVG Volume (30 Days)
- TENX 20.7K
- CARM 216.6K
- Earning Date
- TENX 05-13-2025
- CARM 05-08-2025
- Dividend Yield
- TENX N/A
- CARM N/A
- EPS Growth
- TENX N/A
- CARM N/A
- EPS
- TENX N/A
- CARM N/A
- Revenue
- TENX N/A
- CARM $19,632,000.00
- Revenue This Year
- TENX N/A
- CARM $5.59
- Revenue Next Year
- TENX N/A
- CARM N/A
- P/E Ratio
- TENX N/A
- CARM N/A
- Revenue Growth
- TENX N/A
- CARM 31.59
- 52 Week Low
- TENX $2.77
- CARM $0.20
- 52 Week High
- TENX $7.89
- CARM $2.05
- Technical
- Relative Strength Index (RSI)
- TENX 49.26
- CARM 22.51
- Support Level
- TENX $6.00
- CARM $0.35
- Resistance Level
- TENX $6.76
- CARM $0.46
- Average True Range (ATR)
- TENX 0.40
- CARM 0.04
- MACD
- TENX 0.02
- CARM -0.02
- Stochastic Oscillator
- TENX 39.47
- CARM 8.63
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.